title: Fenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice.
abstract: The aim was to prepare fenofibrate nanoliposome (FNB-Nanolipo) and investigate its characterizations, oral pharmacokinetic (PK) profiles as well as preventive and therapeutic effects on nonalcoholic fatty liver disease (NAFLD) induced by a methionine choline deficient (MCD) diet in mice. The prepared FNB-Nanolipo showed high drug loading capacity and sustained in vitro FNB release profile. Compared to FNB crude drug at equal doses, the FNB-Nanolipo given at 20 mg/kg/day (beginning on the same day when the MCD diet feeding started and lasted for 7 days) or 40 mg/kg/day (beginning after 7 days of the MCD diet feeding and lasting for another 7 days together with the MCD diet) increased plasma FNB concentration of the mice by 11.8-fold (P<0.05) or 57.3-fold (P<0.001), respectively, and reduced 54.7% (P<0.05) or 35.5% (P<0.05) of excessive hepatic lipid, respectively. The results suggest that the FNB-Nanolipo could not only significantly prevent but also efficiently treat NAFLD.
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China.
authors.forename: Yini
authors.initials: Y
authors.lastname: Cao
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Xu
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China.
authors.forename: Cong
authors.initials: C
authors.lastname: Chen
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China.
authors.forename: Yunan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing, China; School of Pharmaceutical Sciences, Peking University, Beijing, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing, China. Electronic address: ronaqi@gmail.com.
authors.forename: Rong
authors.initials: R
authors.lastname: Qi
mesh_terms: D000818:Animals; D002794:Choline; D011345:Fenofibrate / Q000008:administration & dosage / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008081:Liposomes; D008099:Liver; D008715:Methionine; D051379:Mice; D053758:Nanoparticles; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy*
chemical_list: D000960:Hypolipidemic Agents; D008081:Liposomes; D008715:Methionine; D002794:Choline; D011345:Fenofibrate
keywords: Fenofibrate; Methionine choline deficient diet; Nanoliposome; Nonalcoholic fatty liver disease; Plasma concentration